20866-48-2

Usage

Uses

Used in Pharmaceutical Industry:
Boc-Tyr(Boc)-OH is used as a key intermediate in the synthesis of bioactive peptides and pharmaceutical compounds. Its protective Boc groups allow for the controlled assembly of peptide chains, ensuring the proper incorporation of tyrosine residues and facilitating the production of therapeutically relevant peptides.
Used in Peptide Chemistry:
Boc-Tyr(Boc)-OH serves as a crucial building block in peptide chemistry, enabling the protection of the tyrosine side chain during peptide assembly. This protection strategy prevents unwanted reactions, such as side chain oxidation or unwanted coupling, and ensures the successful synthesis of target peptides.
Used in Organic Synthesis:
In organic synthesis, Boc-Tyr(Boc)-OH is utilized for the preparation of various peptides and peptide-related compounds. Its protective Boc groups allow for the controlled synthesis of complex organic molecules, facilitating the production of a wide range of bioactive compounds.
Overall, Boc-Tyr(Boc)-OH is a valuable compound in the fields of pharmaceuticals, peptide chemistry, and organic synthesis, playing a pivotal role in the development and production of bioactive peptides and pharmaceutical compounds.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 60-18-4 L-tyrosine 
• 3978-80-1 Boc-Tyr-OH 

Downstream Products

• 94664-21-8 quinolin-8-yl ester of N,O-di-tert-butoxycarbonyltyrosine 
• 88829-53-2 N-tert-butyloxycarbonyl-O-tert-butyloxycarbonyl-L-tyrosyl-glygylglicine 
• 2387-23-7 1,3-Dicyclohexylurea 
• 96382-72-8 H-Tyr-D-Orn[*]-Phe-Asp[*]-NH2 
• 110172-15-1 H-Tyr-Orn[*]-Phe-Asp[*]-NH₂ 
• 110116-75-1 H-Tyr-D-Asp[*]-Phe-A₂bu[*]-NH₂ 
• 106818-61-5 H-Tyr-D-Orn[*]-Phe-D-Asp[*]-NH₂ 
• 110172-16-2 H-Tyr-D-Orn[*]-D-Phe-Asp[*]-NH₂ 
• 106327-80-4 H-Tyr-D-Orn[*]-Phe(NMe)-Asp[*]-NH₂ 
• 110116-74-0 H-Tyr-D-Orn[*]-Hfe-Asp[*]-NH₂ 
• 106327-79-1 H-Tyr-D-Orn[*]-Phe(p-NO₂)-D-Asp[*]-NH₂ 
• 110116-73-9 H-Tyr-D-Orn<*>-Phg-Asp<*>-NH2 
• 88829-52-1 (S)-2-[(S)-2-(2-{2-[(S)-2-tert-Butoxycarbonylamino-3-(4-tert-butoxycarbonyloxy-phenyl)-propionylamino]-thioacetylamino}-acetylamino)-3-phenyl-propionylamino]-4-methyl-pentanoic acid methyl ester 
• 71764-12-0 (S)-2-tert-Butoxycarbonylamino-3-(4-tert-butoxycarbonyloxy-phenyl)-propionic acid pentafluorophenyl ester 

Relevant academic research and scientific papers

GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

Rhamnolipid inspired lipopeptides effective in preventing adhesion and biofilm formation of Candida albicans

Rhamnolipids are biodegradable low toxic biosurfactants which exert antimicrobial and anti-biofilm properties. They have attracted much attention recently due to potential applications in areas of bioremediation, therapeutics, cosmetics and agriculture, however, the full potential of these versatile molecules is yet to be explored. Based on the facts that many naturally occurring lipopeptides are potent antimicrobials, our study aimed to explore the potential of replacing rhamnose in rhamnolipids with amino acids thus creating lipopeptides that would mimic or enhance properties of the parent molecule. This would allow not only for more economical and greener production but also, due to the availability of structurally different amino acids, facile manipulation of physico-chemical and biological properties. Our synthetic efforts produced a library of 43 lipopeptides revealing biologically more potent molecules. The structural changes significantly increased, in particular, anti-biofilm properties against Candida albicans, although surface activity of the parent molecule was almost completely abolished. Our findings show that the most active compounds are leucine derivatives of 3-hydroxy acids containing benzylic ester functionality. The SAR study demonstrated a further increase in activity with aliphatic chain elongation. The most promising lipopeptides 15, 23 and 36 at 12.5 μg/mL concentration allowed only 14.3%, 5.1% and 11.2% of biofilm formation, respectively after 24 h. These compounds inhibit biofilm formation by preventing adhesion of C. albicans to abiotic and biotic surfaces.

Sequential Intermolecular Radical Addition and Reductive Radical Cyclization of Tyrosine and Phenylalanine Derivatives with Alkenes via Photoinduced Decarboxylation: Access to Ring-Constrained γ-Amino Acids

Sequential radical addition to alkenes and reductive radical cyclization of phenylalanine and tyrosine derivatives via photoinduced decarboxylation furnished ring-constrained γ-amino acids under mild conditions. A variety of alkenes such as acrylamides and acrylic esters could be employed in the photoinduced radical cascade cyclization. The yields of the ring-constrained γ-amino acids are dependent on the electron-accepting ability and steric hindrance of the alkene used. The proposed sequential reaction can also be applied for direct tethering of dipeptides to yield unique ring-constrained tetrapeptides.

DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18F]FLUOROMETHYL) TYROSINE

The invention describes novel direct synthesis methods for converting a precursor into a PET-tracer with a 18F-fluoromethoxy-group. The invention is also directed to novel and stable precursors for the direct radiosynthesis of protected derivatives of O- ([18F]Fluoromethyl) tyrosines.

New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine

The invention describes novel and stable precursors for the direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosines, and methods for obtaining thoses compounds.

Base-labile tert-butoxycarbonyl (Boc) group on phenols

Phenols are deprotected with weak bases from their tert-butoxycarbonyl (Boc) derivatives. Boc deprotection with bases can avoid side reactions during the deprotection with acids. We note the lability of the Boc to bases and are able to utilize it as a new cleavage condition for synthetic studies.

Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells

A previously disclosed series of non-nucleoside allosteric inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) was optimized to yield novel compounds with improved physicochemical properties and activity in cell-based assays. Replacement of ionizable carboxylic acids with neutral substituents in lead compounds produced inhibitors with cellular permeability and antiviral activity in a cell-based assay of subgenomic HCV RNA replication (replicon EC50 as low as 1.7 μM. The improvement in potency in this ex vivo model of HCV RNA replication validates, in part, the mechanism by which this class of allosteric benzimidazole derivatives inhibits the polymerase and represents a significant step forward in the discovery of novel HCV therapeutics.

Viral polymerase inhibitors

A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-3)alkyl, (C6-10)bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R3 is selected from H, (C1-6)alkyl, (C3-6)cycloalkyl, (C36)cycloalkyl(C1-6)alkyl, (C6-10)aryl, (C6-10)aryl(C1-6)alkyl, (C2-6)alkenyl, (C3-6)cycloalkyl(C2-6)alkenyl, (C6-10)aryl(C2-6)alkenyl, N{(C1-6)alkyl}2, NHCOO(C1-6)alkyl(C6-10)aryl, NHCO(C6-10)aryl, (C1-6)alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.

3, 5-disubstituted and 3, 4, 5-trisubstituted 2-isoxazolines and isoxazoles, process for their preparation and their use as pharmaceuticals

A compound having the formula (I), a physiologically tolerable salt of the compound having the formula (I) and/or a steroisomeric form of the compound having the formula (I), in which one residue R1 or R2 stands for the formula (II),